Bill > S3064

This bill aims to improve access to non-opioid pain management drugs for Medicare Part D beneficiaries by making several key changes to Medicare prescription drug coverage. Starting in January 2026, the bill requires that qualifying non-opioid chronic pain management drugs be placed on the lowest cost-sharing tier, have no deductible applied, and be free from step therapy or prior authorization requirements. To qualify, a drug must be FDA-approved for treating specific chronic pain conditions (such as diabetic neuropathy, fibromyalgia, and neuropathic pain), not act on opioid receptors, have no therapeutic equivalents on the market, and have a monthly wholesale acquisition cost below a specified threshold. The bill applies to both standard Medicare Part D plans and plans for low-income individuals, ensuring that patients with chronic pain have easier and more affordable access to alternative pain management medications without being required to try opioids first or obtain complex pre-approvals from their insurance plan.